CORAL SPRINGS, FL -- (Marketwire) -- 04/30/12 -- FinancialNewsMedia.com "stocks to watch" for today: Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), Barnes & Noble, Inc. (NYSE: BKS), Gen-Probe Incorporated (NASDAQ: GPRO), SEFE, Inc. (OTCBB: SEFE).
Breaking News Alert: Monday before the markets opened for trading, Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc., Secures $20,000,000 In Institutional Funding. Southridge Partners is to provide the $20 million in funding for the rapid commercialization of stem cell therapies.
Regen BioPharma has developed a vertically-integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.
To date, Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. Once the technology is secured, the Company anticipates partnering with industry leading scientists, physicians, and service providers to complete the Investigational New Drug (IND)-enabling work and begin clinical trials.
"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix. "We are assembling the team and capabilities to in-license and evaluate technologies rapidly, then to develop the regulatory package and initiate clinical trials. Our business model and partnerships will allow us to take cell therapy products from discovery to FDA Phase II clinical trials in as short a period as 18 - 24 months."
Read the entire BMSN press release announcing Bio-Matrix Scientific Group's new subsidiary, Regen BioPharma, Inc. along with their full disclosure here: http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=148
Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com.
Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup
Barnes & Noble, Inc. (NYSE: BKS) announced that Microsoft will make a $300 million investment in a new Barnes & Noble subsidiary. BKS is up over 90% and 3.4Mill shares traded so far in pre-market trading. (4/30/12).
Gen-Probe Incorporated (NASDAQ: GPRO) announced this morning before the markets open that Hologic, Inc. will acquire all the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion. GPRO is up over 19% and 1.8Mill shares traded so far in pre-market trading. (4/30/12).
SEFE, Inc. (OTCBB: SEFE) introduced a summary of its tether contact system and its role in the company's flagship Harmony III product. SEFE was up over 4% in early trading on when the markets opened this morning. (04/30/12)
If you're a company interested in having FN Media Group assist you with creating a greater awareness for your next news release utilizing our multi-media and leading edge outreach solutions, contact us now at firstname.lastname@example.org
DISCLAIMER: FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For disseminating this release, FNMG expects to be compensated by a non-affiliated third party five thousand dollars per week for continued coverage of Bio-Matrix Scientific Group, Inc (PINKSHEETS: BMSN) News. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.